Development of antiviral therapy for severe acute respiratory syndrome.
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.
Cinatl
Jindrich
J
Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de
Michaelis
Martin
M
Hoever
Gerold
G
Preiser
Wolfgang
W
Doerr
Hans Wilhelm
HW
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D018352:Coronavirus Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D004196:Disease Outbreaks; D015195:Drug Design; D006801:Humans; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000276:immunology; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D014765:Viral Vaccines / Q000276:immunology
D000998:Antiviral Agents; D014765:Viral Vaccines